Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.